Company Filing History:
Years Active: 2012-2017
Title: Falk Nimmerjahn: Innovator in IgE-Mediated Disease Treatment
Introduction
Falk Nimmerjahn is a notable inventor based in Erlangen, Germany. He has made significant contributions to the field of medical science, particularly in the treatment of diseases mediated by IgE antibodies. With a total of 2 patents, his work has the potential to impact many lives.
Latest Patents
Nimmerjahn's latest patents include a treatment for IgE-mediated disease. This invention provides an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, for use in a method for treating or preventing a disease or condition mediated by IgE antibodies. Another significant patent is a method of assessing the glycosylation state or functional quality of an IgG containing sample. This invention offers methods and kits for the dissociation of Fcγ-receptor-IgG complexes, as well as methods and kits for the isolation of IgG and Fc and Fab fragments of IgG.
Career Highlights
Throughout his career, Falk Nimmerjahn has worked with prominent companies in the biotechnology sector, including Genovis AB and Hansa Medical AB. His expertise and innovative approach have made him a valuable asset in these organizations.
Collaborations
Nimmerjahn has collaborated with several professionals in his field, including Maria Allhorn and Mattias Collin. These partnerships have further enhanced his research and development efforts.
Conclusion
Falk Nimmerjahn is a distinguished inventor whose work in IgE-mediated disease treatment showcases his commitment to advancing medical science. His patents and collaborations reflect his dedication to improving healthcare outcomes.